OPINION New insights into the mechanisms of the ketogenic diet
INTRODUCTION
Since ancient times, it was known that sustained fasting or a 'water diet' can be used to control seizures in epilepsy. In the 1920s, it was found that a diet composed mostly of fats, that is, a high-fat, low-carbohydrate 'ketogenic diet', could replicate the effects of fasting, and those beneficial effects were ascribed to the production of ketones, such as b-hydroxybutyrate (BHB), acetoacetate, and acetone in the liver [1] . Despite early successes of ketogenic diet therapies, the advent of antiepileptic drugs (AEDs) in the 1940s pushed ketogenic diet therapy to the sidelines. However, the clinical use of ketogenic diet therapies received increased attention in the 1990s, and ketogenic diet therapy is now an established therapy for difficult-to-treat epilepsies in addition to a wider use in a variety of neurological disorders [2] . Seizure freedom during ketogenic diet treatment is a clinical reality with one study reporting a 24% rate of seizure freedom; however, there is still a risk of breakthrough seizures [3] . Core mechanisms of the diet have been covered in excellent recent reviews [4] [5] [6] . This review focuses on new mechanistic findings, which support the concept that the broad success of ketogenic diet therapy is based on a combination of multiple beneficial mechanisms. The purpose of this review is not to provide a comprehensive overview of all potential mechanisms, but to guide the reader to areas of current research interest.
CLINICAL ASSOCIATIONS
Clinical studies can be used to associate metabolites or neurotransmitters/modulators mobilized by ketogenic diet therapy with treatment success and to identify predictors for successful therapeutic outcomes. For example, it is well known that high-blood BHB levels correlate with positive treatment outcome. Similarly, an increase in cholecystokinin-8, a peptide with antiepileptic properties, and a decrease in leptin was associated with seizure suppression in patients with refractory epilepsy [7] . On the amino acid level lysine and arginine changes in cerebrospinal fluid were associated with >50% seizure reduction in a study involving 60 children [8] . On the genomic level, single-nucleotide polymorphisms can be used to associate gene variants with treatment success. However, variants in KCNJ11 and B-cell lymphoma 2-associated death promoter (BAD), two key metabolic regulators, were recently shown to not predict response to ketogenic diet therapy [9] .
KETOSIS AND KETONE BODIES
Ketone bodies, such as BHB, and their derivatives have received most attention as mediators of the antiseizure, neuroprotective, and anti-inflammatory effects of ketogenic diet therapy [1, 10, 11] . In neurons, BHB can compete with glucose for energy generation by inhibiting glycolytic flux upstream of pyruvate kinase [12 & ]. Ketogenic diets can thereby shunt ketones into oxidative metabolism in the brain, which also enhances the capacity to produce amino acids such as gamma-aminobutyric acid [13] . BHB levels in plasma are generally taken as indicator for ketosis but interactions with conventional AEDs may exist [14] . Traditionally, BHB has been considered as the main effector of the therapeutic benefits of ketogenic diet therapy. BHB in turn appears to have pleiotropic effects. In one mechanistic study, BHB was shown to support synaptic vesicle recycling with a net effect of endocytosis exceeding exocytosis, a mechanism with possible anticonvulsant outcome [15] . BHB can also have direct effects by acting as endogenous ligand of the hydroxylcarboxylic acid receptor 2 (HCA2) [11] . Activation of HCA2 on a subset of macrophages induces a neuroprotective phenotype depending on prostaglandin D2 production, whereas the genetic ablation of HCA2 abolishes BHB-induced neuroprotection in a murine stroke model [11] . One therapeutic goal is to replace the ketogenic diet, and its strict requirements for adherence, with dietary supplements that can produce sustained ketosis. Ketone esters, such as R,S-1,3-butanediol acetoacetate diester are currently considered as a substitute to ketogenic diet therapy in efforts to develop a 'ketogenic diet in a pill'. In support of therapeutic efficacy, R,S-1,3-butanediol acetoacetate diester was shown to increase the thresholds for pentylenetetrazole-induced seizures in the rat [16] and to ameliorate seizures in a mouse model of Angelman syndrome [17] .
MEDIUM-CHAIN FATTY ACIDS
The medium-chain triglyceride ketogenic diet is commonly used for the treatment of refractory childhood epilepsy. Importantly, one-on-one comparisons of a variety of medium-chain fatty acids with valproic acid, a conventional AED, showed enhanced antiseizure efficacy of medium-chain fatty acids with reduced toxicities compared with valproic acid in a panel of in-vitro and in-vivo assays [18] . Mediumchain fatty acids, such as heptanoic acid, octanoic acid, or decanoic acid, exert pleiotropic antiseizure effects and have therefore been considered as add-ons to ketogenic diets or to regular nonketogenic diets. Heptanoic acid can supply the tricarboxylic acid cycle with both acetyl-CoA for energy production and propionyl-CoA to replenish the cycle. It has been shown that heptanoic acid can lead to increased levels of glutamine in the brains of glucose transporter I-deficient mice suggesting a role for glial metabolism of heptanoate [19] . A small-scale, open-label case series tested the effects of triheptanoin-supplemented diets in 14 patients with inborn glucose transporter type I deficiency. The authors of this study reported a modest improvement in ictal events, but the underlying mechanisms were not further evaluated [20] . Branched octanoic acid compounds have been generated that show promising antiseizure activity in in-vitro and in-vivo seizure
KEY POINTS
The antiepileptic effects of ketogenic diet therapy are based on a combination of multiple beneficial mechanisms.
Certain lipids, such as medium-chain fatty acids, have their own independent anticonvulsant effects that may boost the efficacy of ketogenic diet therapy, or that may lead to replacement therapies.
Decanoic acid controls seizures through direct AMPA receptor inhibition.
Drugs targeting LDH reduce seizures through inhibition of a metabolic pathway.
Ketogenic diet therapy exerts disease modifying, antiepileptogenic effects that are based on an epigenetic mechanism. models, without affecting histone deacetylase activity [21] . Chronic feeding of diet with 35% of the calories derived from tridecanoin but not from trioctanoin was anticonvulsant in two mouse models in the absence of increased plasma and brain BHB [22 & ]. Only tridecanoin but not trioctanoin improved mitochondrial metabolic functions and antioxidant capacity [22 & ]. Specifically, decanoic acid but not octanoic acid improved mitochondrial biogenesis as well as mitochondrial numbers through a peroxisome proliferator-activated receptors (PPAR)g-mediated mechanism in neuronal cell culture systems [23, 24] ; decanoic acid led to an increase in the transcription of genes related to fatty acid metabolism while downregulating genes involved in glucose metabolism [23] . Using single-cell imaging in pluripotent stem cell-derived human astrocytes and neurons, it was found that decanoic acid promoted astrocytic but not neuronal glycolysis and lactate formation, whereas octanoic acid did not affect glycolysis but increased astroglial ketogenesis [ ], identified an exciting novel mechanism, by which decanoic acid directly reduces neuronal excitability by inhibition of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor activity; importantly, it was shown that decanoic acid acts as a noncompetetive AMPA receptor antagonist binding to a site that is distinct from the perampanel-binding site of the receptor. These findings suggest the existence of a powerful anticonvulsant mechanism of mediumchain triglyceride ketogenic diets, which is based on the direct inhibition of excitatory neurotransmission by decanoic acid.
POLYUNSATURATED FATTY ACIDS
A classic ketogenic diet consists mostly of longchain saturated triglycerides; however, polyunsaturated fatty acids (PUFAs) may also decrease neuronal 
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS AND INFLAMMATORY PATHWAYS
Inflammatory pathways and oxidative stress play a major role in the pathophysiology of epilepsy. Of interest, ketogenic diet therapy exerts a major inherent anti-inflammatory activity, which appears to be independent of PUFAs [30 & ]. The metabolically regulated transcription factors of the family of PPAR are involved in mitochondrial biogenesis and the control of genes involved in anti-inflammatory and antioxidant pathways. PPARa is activated by X-boxbinding protein 1, which is activated by hepatic serine/threonine-protein kinase/endoribonuclease inositol-requiring enzyme 1, which in turn functions as a nutrient sensor that regulates metabolic adaptation to fasting [31] . PPARg is activated by fatty acids, such as decanoic acid, and might therefore mediate anti-inflammatory and antioxidant properties of the ketogenic diet. A PPARg antagonist abrogated ketogenic diet-induced seizure protection in voltagegated potassium channel 1.1 (Kv1.1) knockout mice, a spontaneously epileptic mouse strain responsive to ketogenic diet therapy [32] , whereas an PPARg agonist conferred seizure protection; in line with these findings ketogenic diet therapy was ineffective in preventing seizures in PPARg knockout mice [33 & ].
As seizure suppression was associated with a PPARginduced increase in PPARg 2 expression, the authors of this study concluded that PPARg 2 contributes to the antiseizure effects of ketogenic diet therapy.
ATP-SENSITIVE POTASSIUM CHANNELS
The ATP-sensitive potassium (K ATP ) channel is a sensor for the energy state of the cell and acts as a feedback system to restrict neuronal firing, when energy levels are low. K ATP activity is determined by phosphoregulation of BAD, a protein with dual functions in apoptosis and glucose metabolism. Genetic manipulation of BAD designed to reduce glucose metabolism produced an increase in the activity of neuronal K ATP channels and resistance to seizures in vivo [34] . In line with those findings, pharmacological inhibition or genetic manipulation of K ATP function abrogated or attenuated ketone-induced neuroprotection and seizure resistance [34,35 & ]. In the substantia nigra, K ATP channels are activated under conditions that favor decreased mitochondrial respiration [36] . Together these findings suggest a tight mechanistic link between metabolism, BAD, K ATP channel function, and the control of neuronal excitation.
NEUROTROPHIC FACTORS
The neurotrophin brain-derived neurotrophic factor (BDNF) is linked to both AMP kinase and mammalian target of rapamycin (mTOR signaling) and thought to be implicated in epileptogenesis. A ketogenic diet, but not a high-fat or a low-fat diet, led to a circadian shift in the expression of brain and liver BDNF, suggesting that a ketogenic diet might impact circadian activities and the expression of BDNF [37] . However, the significance of neurotrophic factors as possible mediators of ketogenic diet therapy is not yet clear, because in healthy rats a ketogenic diet reduced BDNF levels in striatum, but not hippocampus, whereas the astrocyte neurotrophic cytokine S100 calcium-binding protein B (S100b) was not affected in the brain [38] .
INCREASED MITOCHONDRIAL FUNCTION AND BIOGENESIS
Mitochondrial function is crucial for brain function and several inborn metabolic disorders compromise mitochondrial function and trigger complex clinical phenotypes with seizures. Ketogenic diet therapy is known to improve mitochondrial function and is therefore considered for the treatment of metabolic seizure disorders. One of those conditions is brain aspartate-glutamate carrier deficiency, which affects a transporter that shuttles aspartate from mitochondria to the cytosol and indirectly promotes the transfer of nicotinamide adenine dinucleotide-reducing equivalents into mitochondria, and which causes hypotonia, impaired psychomotor development, and seizures. A recent case report demonstrated that ketogenic diet treatment was able to compensate for the metabolic defects with major improvement of clinical symptoms [39 & ]. Glucose and mitochondrial hypometabolism contributes to the disorder Dravet syndrome, a catastrophic form of childhood epilepsy. A ketogenic diet formulation rescued mitochondrial respiration and restored glucose metabolism in a zebrafish model of Dravet syndrome [40 & ]. The underlying molecular mechanism through which a ketogenic diet in general, and ketone bodies in particular, improve mitochondrial function has been unraveled in a recent study that investigated the effects of ketone bodies on acutely isolated brain mitochondria from Potassium Voltage-Gated Channel Subfamily A Member 1 (Kcna1) knockout mice [41 && ]. The authors of this study demonstrated that ketone bodies alone suppressed seizures in spontaneously epileptic Kcna1-null mice, restored impaired hippocampal long-term potentiation and learning in those mutants, and raised the threshold for calcium-induced mitochondrial permeability transition (mPT). Importantly, the targeted deletion of the cyclophilin D subunit of the mPT complex uncoupled the effects of ketone bodies on mPT, while mPT was directly related to the antiseizure effects of ketone bodies; therefore, the direct link between ketone bodies, mPT, and seizure control indicates a mechanistic explanation for the antiseizure effects of ketogenic diet therapy [41 && ].
OXIDATIVE STRESS
Among a multitude of detrimental downstream pathways, oxidative stress leads to the formation of reactive lipid fragments that can further aggravate tissue damage. Isotope-labelling experiments have shown that ketogenic diet therapy induces cytochrome P450 4A-dependent v and v-1-hydroxylation of reactive lipid species, a novel mechanism that might contribute to the anti-inflammatory properties of ketogenic diet therapy [42] .
PROTEIN RESTRICTION
It needs to be kept in mind that a strict ketogenic diet regimen not only restricts the supply of carbohydrates, but also of proteins. Protein restriction itself has been shown to enhance the production of the endocrine signal fibroblast growth factor 21 in the liver [43] . Fibroblast growth factor 21 in turn can increase glucose uptake by adipocytes and reduce blood glucose levels, an additional beneficial effect that might be attributable to low protein content in certain ketogenic diets.
LACTATE DEHYDROGENASE
The astrocyte-to-neuron lactate shuttle is a major component of a metabolic route that supplies the neuron with alternate sources of energy. Lactate dehydrogenase (LDH) is a metabolic enzyme mediating this lactate shuttle and needed to supply neurons with glucose-derived energy (via lactate). ]. These findings are remarkable and suggest that inhibition of this metabolic pathway can mimic the effects of ketogenic diet therapy, and might lead to the development of a 'ketogenic diet in a pill'.
DISEASE-MODIFYING AND EPIGENETIC MECHANISMS
A series of recent data suggests that ketogenic diet therapy exerts disease-modifying effects in epilepsy and that epigenetic mechanisms might be involved. Strikingly, ketogenic diet therapy was found to postpone disease progression, delay the onset of severe seizures, and to increase the lifespan of Kcna1-null mice, a model of progressive epilepsy and sudden unexpected death in epilepsy [45 && ]. A disease-modifying epigenetic mechanism of ketogenic diet therapy is supported by findings that a predominant increase of DNA methylation is associated with chronic epilepsy in the rat and that ketogenic diet therapy attenuated seizure progression and ameliorated DNA methylation-mediated changes in gene expression [46] . A subsequent study showed that a transient ketogenic diet therapy restored normal adenosine levels and global DNA methylation levels in epileptic rats that were otherwise adenosine deficient and hypermethylated; importantly, transient ketogenic diet therapy reduced seizure activity long-term, even after diet reversal to control diet [47 && ]. Because ketogenic diet therapy increases adenosine [47 && ,48] and because adenosine blocks DNA methylation [49] , it is likely that the ketogenic diet exerts its disease-modifying effects through an adenosine-dependent epigenetic mechanism.
GUT MICROBIOME
The gut microbiome is increasingly recognized to play a major role for brain health. A recent study found that ketogenic diet feeding in the BTBR mouse model of autism resulted in antimicrobial effects and a compositional remodeling of the gut microbiome [50 && ]. Although the underlying mechanisms remain enigmatic, this is a significant finding suggesting a much broader systemic effect of ketogenic diet therapy.
CONCLUSION
The ketogenic diet combines several mechanisms that together reduce neuronal excitability. The identification of specific mechanisms may lead to the development of treatments in which a strict ketogenic diet might be replaced by dietary supplements. The identification of disease-modifying properties of ketogenic diet therapy may offer hope for long-lasting therapeutic outcomes even after discontinuation of the diet. 
